Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial.
Saved in:
| Title: | Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial. |
|---|---|
| Authors: | Gao, Zhiyuan1 (AUTHOR), Mao, Yajie1 (AUTHOR), Sun, Yichen1 (AUTHOR), Tong, Liping1 (AUTHOR), Liu, Honggang1 (AUTHOR), Wang, Tianhu2 (AUTHOR), Shao, Changjian1 (AUTHOR) 15102905829@163.com, Duan, Hongtao1 (AUTHOR) 646041852@qq.com, Yan, Xiaolong1 (AUTHOR) yanxiaolong@fmmu.edu.cn |
| Source: | Thoracic Cancer. Aug2025, Vol. 16 Issue 16, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17597706 |
|---|---|
| DOI: | 10.1111/1759-7714.70149 |
